ERBB2 and neoplasm: To evaluate the rate of conversion of receptor status (HER2, ER and PR) between the primary tumor and the recurrent lesion in patients with advanced breast cancer, the GEICAM 2009-03 ConvertHER study reported that HER2 expression is the most stable while the progesterone receptor showed the highest rate of conversion.